43rd ICAAC Main Index



Medical Advocates for Social Justice
Conference Highlights: Select Conference News. Abstracts and Posters from the

		43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Chicago, IL USA September 14-17 , 2003

Main New/Newsworthy Conference Updates: Main Page Home

Last Update: December 08, 2014
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader 5.

Recent Additions

Date Format Document

Sep 17 Poster Predictive Value of Drug Levels; HIV Genotyping, and the Genotypic Inhibitory Quotient (GIQ) at Different Time--Points along 48 Weeks using a SQV/RTV Salvage Therapy

Sep 17 Poster Two-Year Analysis of Stavudine Extended-Release/Prolonged Release Capsules (XR/PRC)as Compared to Stavudine Immediate-Release (IR): Efficacy and Safety

Sep 17 Poster Pharmacokinetic (PK) Evaluation of the Combination of Atazanavir (ATV),
Enteric Coated Didanosine (ddI-EC),and Tenofovir Disoproxil Fumarate
(TDF) for a Once-Daily Antiretroviral Regimen

Sep 17 News Release Significant Response Seen with Boosted Saquinavir at Almost One Year In Protease Inhibitor-Experienced HIV Patients

Drug Data

Abacavir

Study Assessing Once Daily Abacavir (ABC) in a Once Daily ART Regimen
Presented at ICAAC
September 16, 2003
News Release

Study Evaluates Abacavir (ABC), Lamivudine (3TC) and Efavirenz (EFV) Versus Zidovudine (ZDV), Lamivudine (3TC) and Efavirenz in Treatment-Naive Patients
September 14, 2003
News Release

Atazanavir

PDF POSTER
Pharmacokinetic (PK) Evaluation of the Combination of Atazanavir (ATV), Enteric Coated Didanosine (ddI-EC),and Tenofovir Disoproxil Fumarate (TDF) for a Once-Daily Antiretroviral Regimen
S Kaul, K Bassi, B Damle, et al
PDF Poster

Didanosine

POWER-POINT PRESENTATION
Didanosine (ddI) in treatment-experienced HIV-infected patients: Results from a randomized double-blind placebo-controlled study (AI454-176 - JAGUAR)
J-M. Molina, AG Marcellin, J Pavie, et al
Conference Presentation

Enfuvirtide

	PDF POSTER Durability of Response to Enfuvirtide through 48 Weeks of Response to Enfuvirtide in the TORO Trials Trottier B, Arastéh K, Henry K, et al PDF Poster
	PDF POSTER Safety of Enfuvirtide (ENF) through 48 Weeks of Therapy in the Toro Trials Eron J, Delfraissy J-F, Kuritzkes D, et al. PDF Poster
	New Data Show FUZEON-Based Regimens Continue to Provide Significant Durable Response in Treatment-Experienced HIV Patients Through 48 Weeks September 15, 2003 News Release

Lopinavir

PDF POSTER
Lopinavir/ritonavir in Antiretroviral-Naive HIV-Infected Patients: 5-Year Follow-Up
J Eron, B da Silva, M King, et al
PDF Poster

PDF POSTER
Evolution of Lopinavir (LPV) Resistance in Protease Inhibitor-Experienced Patients Treated with LPV/r
M King, H Mo, A Molla, et al;
PDF Poster

PDF POSTER
Gastrointestinal Tolerability After PI/NNRTI Substitution with Lopinavir/ritonavir
Sension, Y Shen, L Bush, et al
PDF Poster

Kaletra-based Regimen Demonstrated Viral Suppression for Patients New to Therapy in Five-year HIV Trial
September 15, 2003
News Release

Nevirapine

CONFERENCE PDF POSTER
Nevirapine And Efavirenz Have a Comparable Viral Decay Rate Which Is Not Associated With Virologic Failure
F Van Leth, C Huisamen, R Badero, et al
PDF Poster Abstract

2NN Sub-Study Finds HIV Treatment Regimens Containing Viramune or Efavirenz Demonstrate a Comparable Viral Decay Rate
September 15, 2003
News Release

Saquinavir

CONFERENCE PDF POSTER
Predictive Value of Drug Levels; HIV Genotyping, and the Genotypic Inhibitory Quotient (GIQ) at Different Time--Points along 48 Weeks using a SQV/RTV Salvage Therapy
L. Valer, D. Gonzalez de Requena, C. de Mendoza, et al
PDF Poster

Significant Response Seen with Boosted Saquinavir at Almost One Year In Protease Inhibitor-Experienced HIV Patients
September 17, 2003
News Release

Stavudine

PDF POSTER
Two-Year Analysis of Stavudine Extended-Release/Prolonged Release Capsules (XR/PRC)as Compared to Stavudine Immediate-Release (IR): Efficacy and Safety
H Brett-Smith, L Reynolds, L Bessen, V Rutkiewicz
PDF Poster

HIV Drug Monitoring

UCLA Study Demonstrates Utility of ViroLogic Co-Receptor Tropism And Replication Capacity Assays as Predictors of HIV Progression
September 15, 2003
News Release

Main New/Newsworthy Conference Updates: Main Page Home

43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
A Medical Advocates for Social Justice Update